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Background: We evaluated the possibility of restoring a physiologic vascular wall using undifferentiated mesenchymal
stem cells (MSCs) seeded on a polyurethane vascular prosthesis.
Methods:UndifferentiatedMSCs were seeded on a vascular prosthesis and implanted intoWistar male rats (weight, 350 g)
to investigate differentiation into smooth muscle cells and to determine graft endothelialization in vivo.
Results: Seeded or nonseeded grafts were surgically implanted. Undifferentiated MSCs were first labelled for green
fluorescent protein. After 2 weeks in vivo, MSC that were initially self-expanded on the graft in a monolayer were
organized in amulticellular layer mimickingmedia of aortic adjacent wall. They coexpressed green fluorescent protein and
smooth muscle proteins that were not present before the in vivo engraftment, indicating that in vivo conditions induced
smooth muscle protein maturation. Undifferentiated MSC showed an electrophysiologic profile quite different than
mature smoothmuscle cells. In both in vitro- and in vivo-differentiatedMSCs, adenosine triphosphate, an IP3-dependent
agonist, induced an increase in calcium similar to that which occurred in mature smooth muscle cells. However, MSCs
failed to respond to caffeine, a ryanodine receptor activator, indicating the absence of mature calcium signaling, and
finally, contraction was absent. Endothelialization attested by immunohistology and scanning electron microscopy was
greater in MSC-seeded grafts that prevent thrombosis.
Conclusion: Only partial smooth muscle cell differentiation of MSCs resulted when seeded on vascular grafts, but MSCs
spontaneously restore a media-like thick wall. Mesenchymal stem cells have a positive impact on in vivo endothelialization
in rats that supports their potential for use in vascular surgery.
Clinical Relevance: Thrombosis of vascular prostheses is a major complication of surgery. We showed on rat aorta that
mesenchymal stem cells seeded on polyurethane patch restore endothelium. It also induced incomplete smooth muscle
differentiation. In the future, stem cell could prevent thrombosis of vascular prostheses. (J Vasc Surg 2008;47:1313-21.)Despite technologic advances in biomaterials, the sur-
gical impact of small-sized vascular prostheses in peripheral
vascular bypass surgery has been poor, with a positive
outcome reported as low as 50% at the 1-year follow-up.
Bioengineering of vascular grafts using stem cells could
promote endothelialization, thus preventing thrombosis.
To this end, several studies have attempted to cover the
graft directly using endothelial cells.1 In 1984 Herring et
al2 described, for the first time, the use of endothelial cells
to cover vascular grafts. Endothelialization was observed
more often with polytetrafluoroethylene (PTFE) than with
a Dacron graft. However, seeded grafts were covered
largely by fibroblasts.2 Bhattacharya et al3 showed that
CD34 cell seeding enhances vascular graft endothelializa-
tion in a dog model. These promising results were over-
shadowed, however, by the difficulty in obtaining high-
quality coverage of grafts. Furthermore, endothelial cells
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Although collagen coating improves primary cellular
adhesion, the degree of spreading depends on the underly-
ing surface structure and on the application of shear stress.4
Recent procedures involved the pretreatment of prosthesis
material with fibrin, collagen, or other matrix molecules
that promote cell attachment and retention, but clinical
relevance of these biomaterials have to be confirmed by
large, human studies.5,6
Endothelial progenitors alone or cocultured with myo-
fibroblasts and fibrin preparations give also promising re-
sults.7-9 Mesenchymal stem cells (MSCs) contribute to
angiogenesis in the bone marrow and support hematopoi-
etic cells in adult bone marrow. Because of their multipo-
tent nature, MSCs can maintain cellular plasticity and can
differentiate toward several phenotypes. They are defined
by their adipose, cartilaginous, and osteogenic differentia-
tion capacity.10 Their pluripotency also includes the ability
to develop into a vascular component.11 This vascular
differentiation has only been demonstrated in vitro with
human and mouse MSCs, however, and no study has
clearly shown this type of differentiation in vivo.12,13
These fibroblast-like cells exhibit adherence, expan-
sion, and resistance properties conducive to grafting and
allow the transected by genes to enhance local nitric oxide
1313
JOURNAL OF VASCULAR SURGERY
June 20081314 Mirza et alproduction.14 We therefore hypothesized that undifferen-
tiated MSCs seeded on a vascular prosthesis could differen-
tiate into smooth muscle cells (SMCs) or endothelial cells
alike and contribute to partial wall restoration. Only a few
studies have focused on the use of MSCs for graft engineer-
ing.15 In the study of Cho et al,16 MSCs first differentiated
into SMCs or endothelial cells as before implantation. This
is time-consuming with some restrictions for clinical use.
Hashi et al17 used biodegradable nanofibrous scaffold with
MSCs to prevent thrombosis and vascular remodeling.
In the present study, we focused on the use of undif-
ferentiated cells seeded on vascular grafts implanted in the
rat aorta.We first studied the quality of SMCdifferentiation
by exploring MSC functional proprieties to determine if
MSCs allowed restoring a physiologic vascular wall. Finally,
we evaluated the quality of the endothelial covering after 1
to 2 weeks in vivo compared with nonseeded grafts.
MATERIAL AND METHODS
Isolation of mesenchymal stem cells. Cell isolation
and culture procedures forMSCs have been established and
published previously.18-20 Briefly, femurs were aseptically
harvested from 6- to 8-week-oldWistar rats, and the adher-
ent soft tissue was removed. Whole marrow plugs were
obtained by flushing the bone marrow cavity with an 18-
gauge needle set with a syringe filled with culture growth
medium composed of Modified Eagle Medium Alpha (-
MEM; Invitrogen Corporation, Carlsbad, Calif) supple-
mented with 20% fetal calf serum (FCS; HyClone, Logan,
Utah), with an antibiotic solution (1% penicillin/strepto-
mycin; Invitrogen) and an antimycotic solution (0.01%
amphotericin B; Bristol-Myers, New York, NY). The mar-
row plugs were dispersed to obtain a single-cell suspension
by sequentially passing the dispersion through 18- and
22-gauge needles. The cells were centrifuged and resus-
pended with culture medium. Adherent second passage
cells were analyzed by flow cytometry and were positive for
CD90 and CD73, and negative for CD45, confirming that
only MSCs had been selected.
Graft seeding with mesenchymal stem cells. Undif-
ferentiated MSCs were labeled with green fluorescent pro-
tein (GFP) after stable viral gene transfection with LNCX-
GFP vector at the first passage, as previously described.20
Passage twoMSCs were seeded on a vascular prosthesis at a
density of 106/cm2, and grafts were maintained in culture
growth medium for 1 week before surgical intervention.
Undifferentiated MSC-seeded vascular grafts were ob-
served under fluorescent microscopy before implantation
to ensure the overlap quality was 90%.
Animal protocols. All animal investigations were
done accordance with the Guide for the Care and Use of
Laboratory Animals (United States National Institutes of
Health, NIH Publications 85-23, revised 1996), with Eu-
ropean Directives (86/609/CEE), and approved by the
local ethical committee (CREEA).
Thirty-six Wistar male rats (weight, 350 g) were ran-
domly separated into two groups and received either
seeded or nonseeded grafts (Vascular-Patch, Braun, Tut-tlingen, Germany). The first group of rats (n  12) was
used to assess the in vivo differentiation of MSCs into
SMCs after 2 weeks in vivo, and the second group (n 24)
was studied for endothelialization. Within this group, 12
rats received a seeded graft and were euthanized after 1
(n  6) or 2 weeks (n  6), and 12 other rats were
implanted with nonseeded grafts and were euthanized at 1
(n  6) or 2 weeks (n  6) after implantation.
Surgical procedure. Animals were anesthetized with
ketamine (100 mg/kg; Virbac, Carros, France) and largac-
tyl (5 mg/kg; Haupt Pharma, Livron, France) by intraperi-
toneal injection. After median laparotomy, digestive loops
were displaced and the left edge of the aorta was dissected.
Collateral vessels were ligatured and a longitudinal aorto-
tomy was performed to allow the suture of a 1-cm long 
2-mmwide prosthesis beyond the renal arterial bifurcation.
Neither anticoagulation nor antiaggregate treatment was
administrated after recovery.
All rats survived despite the temporary interruption in
intestinal transit during the first days after intervention.
Doppler imaging using a high frequency probe was used to
assess the graft potency before the animals were euthanized
(Sequoia Acuson C256 ultrasonographic system; Moun-
tain View, Calif).
In vivo assessment of smooth muscle cell differenti-
ation. In the first group of rats (n  12), a part of the
prosthesis was analyzed by immunohistology using a Fluo-
View500 confocal microscope (Olympus, Melville, NY)
with a FluoView500 algorithm. Seeded cells were detached
from the second part of the prosthesis after trypsin diges-
tion. These cells were plated in LabTek (Nunc A/S, Rosk-
ilde, Denmark) in a culture growth environment. At con-
fluence, the cells were either fixed and tested for smooth
muscle-specific protein expression by immunohistologic
staining or placed in standard growth medium and used for
an electrophysiologic and functional study (patch clamp,
calcium florescence, and contraction) 1 week.
The smooth muscle protein expression profile (-
smooth muscle actin [SMA], desmin, smooth muscle my-
osin heavy chain [SMMHC], myosin light chain-2
[MLC2]) was compared among undifferentiated MSCs
and in vivo-differentiated MSCs. Cells were incubated with
a primary antibody against rat -SMA, rat desmin, against
rat SMMHC, or rat MLC2 (all from Santa Cruz Biotechnol-
ogy, Santa Cruz, Calif) at 4°C for 12 hours. The antigen–
antibody reaction was detected using a molecular probe
Alexa fluor dye specific secondary or phycoerythrin anti-
body (Interchim, Montlucon Cedex, France) and the pos-
itive reaction was visualized by fluorescent microscopy. The
colocalization with GFP fluorescence was researched.
Reverse transcription–polymerase chain reaction (RT-
PCR) was also performed to assess smooth muscle proteins
encoding genes (a-SMA, desmin, SM-22a, MMHC-11)
expression. The total RNA of rat MSC was isolated using
TRIzol (Invitrogen Gibco-BRL), followed by treatment
with DNase. Reverse transcription was performed using the
RT system Platinum Taq (Invitrogen). RNA (100 ng) was
used in the reaction, and random hexamer primers were
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RT procedure, the reaction mixture (cDNA) was used for
the PCR. The PCR products were electrophoresed through
a 1% agarose gel, and the amplified cDNA bands were
visualized by ethidium bromide staining.
The following were used for the functional assessment
of the MSCs:
Patch-clamp experiments. Electrophysiologic record-
ings were obtained using the conventional patch-clamp
technique in the whole cell configuration. Results for
MSCs were compared with isolated carotid and aortic
arterial cells. Cells were placed in a 0.5-mL volume bath
and continuously superfused by gravity with physiologic
saline solution (PSS) at a rate of 1mL/min. Cell membrane
currents were recorded with an Axopatch 200B patch-
clamp amplifier (Axon Instruments, Union City, Calif).
The net macroscopic currents were generated by stepwise
10-mV depolarizing pulses (400 ms duration, 5-second
intervals) with a constant holding potential of –60 mV
from –100 to 100 mV and normalized to the cell capac-
itance, then expressed in current density. Response to K
channels blockers was recorded after adding an aliquot of
iberiotoxin to a final concentration of 100 nM in the bath
and 4-aminopyridine (3mM) to block the BKCa (20) and
Kv channel types (32), respectively. Both iberiotoxin and
4-aminopyridine were provided by Sigma (Sigma, St-
Quentin Fallaire, France). Voltage-clamp protocols were
generated and the data were captured with a computer
using a Digidata 1200 interface and pClamp8 software
(both Axon Instruments). The analysis was done with
Clampfit 8.1 and Origin 6.0 software (Microcal Software,
Northampton, Mass).
Intracellular Ca2 measurement. Mesenchymal stem
cells were plated on coverslips and loaded with the Ca2-
sensitive fluorescent probe, Fura-2 AM (2 M; 45 minutes
at room temperature). [Ca2]i was estimated from the Fura
2-AM fluorescence using dual-wavelength excitation (340
and 380 nm) and single emission (510 nm). The recording
system included a Nikon Diaphot inverted microscope
fitted with epifluorescence (Nikon France, Charenton-le-
Pont, France). The intensities of the transmitted light were
recorded by one photometer, and single photon currents
were converted to voltage signals. Signals at each wave-
length were digitized and stored on a personal computer
using a PC-Lab Card 812PG interface (Advantech, Nant-
erre, France). The fluorescence ratio (340/380) was calcu-
lated online and displayed with the two voltage signals on a
monitor.
In vitro contraction of mesenchymal stem cells.
Mesenchymal stem cells were plated in a specific glass
chamber in the presence of PSS and observed after attach-
ment to an optical inverted microscope (Olympus IX50)
with a charge-coupled device camera that allowed images
to be recorded continuously. A pipette containing either
ATP (104 mol/L) or potassium chloride (80 mmol/L)
was used with a micromanipulator to prevent the induction
of mechanical stress. A small amount of solution was in-
jected directly onto the cell membrane. Cells were observedbefore and after drogues (ATP and potassium chloride)
infusion.
Endothelialization evaluation. In the second group
of rats (n 24), the collected prostheses were divided into
two parts and used for immunohistologic or electron mi-
croscopic analysis. We evaluated the expression of the spe-
cific endothelial markers, CD31 (platelet/endothelial cell
adhesion molecule [PECAM]), and von Willebrand factor
(vWF), on seeded and nonseeded grafts. Coexpression with
GFP was determined. For scanning electron microscopy,
the vascular patch was fixed in 1% glutaraldehyde, 4%
paraformaldehyde in 0.1M phosphate buffer (pH 7.4),
postfixed in 2% osmium tetroxide, dehydrated in acetone,
critical point-dried using carbon dioxide, and coated by
gold sputtering. Samples were examined with a GEMINI
982 LEO (Carl Zeiss Microimaging, Göttingen Standort
Göttingen-Vertrieb, Deutschland) scanning electron mi-
croscope. All the surfaces were scanned, and 10 consecutive
images representing the whole surface for each prosthesis
were analyzed. Quantitative analysis was done using Opti-
mas software (Imasys, Surennes, France) allowing localiza-
tion of the endothelial surface using a histogram-based
threshold. The endothelial covering area was expressed as a
percentage of the total graft area. A part of prothesis was
also analyzed using JEOL 1010 (JEOL [Europe] SAS,
Croissy-sur-Seine, France) transmission electron micro-
scope in order to ensure the nature of cells after in vivo
implantation. Ultrathin sections cut on Reichert Ultracut E
(Leica Microsystèmes SAS, Rueil-Malmaison, Cedex,
France), were contrasted with uranyl acetate and lead ci-
trate before this last exploration.
Statistical analysis. Values between two groups were
compared using the Mann-Whitney nonparametric test.
Comparison between four groups was performed using a
two-way analysis of variance. When an overall difference
was found, a Holm-Sidak post hoc test of was done. All
statistical analysis was performed using Minitab software
(Minitab Inc, State College, Penn) and SigmaStat 3.0
(SysStat Software Inc, San Jose, Calif). P .05 was consid-
ered statistically significant.
RESULTS
Surgical graft implantation. Twenty-four rats (n 
12 [first group] and n 12 [second group]) were success-
fully implanted with seeded polyurethane grafts and 12
with nonseeded polyurethane grafts (n  12 [second
group]). Aortic flow at the level of prosthesis was recorded
by Doppler ultrasound before euthanasia. All rats im-
planted with a seeded graft (12 of 12 in group 1 and 6 of 12
in group 2) showed a normal flow velocity, whereas one-
third of the rats (4 of 12) that received nonseeded grafts
showed a decrease in aortic flow and exhibited intraaortic
obstructive thrombus formation on necropsy (Fig 1).
Mesenchymal stem cells in vivo proliferation and SMC
differentiation was then evaluated.
Smooth muscle protein expression. Immunohis-
tologic analysis of MSCs before seeding showed high pos-
itive -SMA and GFP signals. No expression of SMMHC
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mature SMCs (Fig 2).
Two weeks after in vivo implantation, a positive signal
for -SMA and GFP was observed on seeded grafts (n 
Fig 1. A, Evaluation of endothelialization by scanning
100; (lower panel) original magnification1000. End
seventh day, although the non-seeded graft was essentially
B, Evaluation of percentage of endothelial surface on see
2 weeks in vivo. *Significantly different P  0.05. C, C
aorta at the level of prosthesis (arrow).
Fig 2. In vivo smooth muscle differentiation. A, Bef
(MSCs) expressed some smooth muscle proteins, includ
smooth muscle myosin heavy chain [SMMHC], myosin
smooth muscle cells. The dark blue shows 4=-6-diamid
implantation, MSCs seeded on graft were collected and
proteins that were not detected before implantation (desm
protein (GFP) verified that the collected cells were the M
Alexa (red) or phycoerythrin (green).12; Fig 3). Sagittal view of the protheses showed thatMSCsthat were initially expended in a monolayer had proliferated
in a thick multicellular layer mimicking the media of adja-
cent aortic vascular wall.
SeededMSCs were thus collected and placed in growth
tron microscopy: (upper panel) original magnification
lial cells (filled arrow) covered the seeded graft from the
red with collagen fibers (clear arrow), even after 14 days.
raft (S) compared with nonseeded graft (NS) after 1 and
ow Doppler shows homogenous flow velocity through
mplantation, undifferentiated mesenchymal stem cells
-smooth muscle actin (SMA) but not others (desmin,
hain-2 [MLC2]) that are normally expressed by mature
-phenylindole [DAPI] nuclei labeling. B, After in vivo
ed in growth medium. They expressed smooth muscle
MMHC,MLC2).C,Coexpression of green fluorescent
initially seeded on the graft. Secondary antibodies wereelec
othe
cove
ded g
olor flore i
ing 
light c
ino-2
plac
in, S
SCsmedium. Of interest was that after 1 week of secondary
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MLC2, and desmin, and also coexpressed a GFP signal,
affirming that these collected cells were the seeded MSCs
(Fig 2). Indeed, in vivo conditions have themselves induced
smooth muscle maturation ofMSCs. Expression of smooth
muscle proteins-encoded genes (a-SMA, Desmin, SM-22a,
MMHC-11) was still present before in vivo implantation.
However SM-22a and MMHC-11 enhanced expression
after in vivo staying (Fig 4).
Functional phenotype characterization of mesen-
chymal stem cells. The current density was lower in un-
differentiated MSCs compared with cells differentiated in
vivo and to carotid and aortic SMCs but enhance after in
vivo implantation. At 90 mV, the current density was
18.2 	 2.5 pA/pF (n  7) for undifferentiated MSCs,
45.8 	 10 pA/pF (n  6) for in vivo differentiated cells
(P  .05), 47 	 2 pA/pF (n  6) for carotid cells (P 
.05), and 38 	 6 pA/pF (n  7) for aortic cells (P  .05).
Pretreatment with 4-aminopyridine (3mM) partially
blocked the outward current on undifferentiated MSCs,
whereas it had a lower effect on in vivo differentiatedMSCs,
suggesting that differentiation decreased 4-aminopyridine–
sensitive channels.
Successive addition of iberiotoxin (100nM) induced a
further decrease in current density. In undifferentiated
MSCs, iberiotoxin inhibited the current by 10 % for all
the different voltage steps studied, whereas it significantly
decreased in vivo–differentiated MSCs (Fig 5). Of interest
was that a similar effect of iberiotoxin was observed in aortic
SMCs, but it had a greater effect in carotid SMCs (Fig 5).
Fig 3. Confocal microscopy analysis of grafts after in vi
A, Before implantation, the frontal view of the prosthe
implantation, mesenchymal stem cell (MSC) smooth mu
prosthesis, and the (C) sagittal view showed that cells w
control aortic vascular wall. D, These cells expressed gr
seeded MSCs. F, Nonseeded graft as a negative control.This demonstrated that iberiotoxin mainly reduced thecurrent inMSCs differentiated in vivo in a similar fashion to
that in aortic SMCs.
Under controlled conditions (cells perfused with PSS),
the resting cytoplasmic calcium concentrations ([Ca2]i)
were similar between undifferentiated and in vivo–
differentiated MSCs. No changes were observed when the
cells were perfused with PSS without calcium (Fig 6). In
both types ofMSCs, ATP (10M), an inositol triphosphate
dependant (IP3) agonist, induced a transient increase in
[Ca2]i. The amplitude of the signal and the percentage of
the responding cells were similar. Similar responses were
observed without an external solution in the bath. Thapsi-
gargin (3 M), a specific inhibitor of the sarcoplasmic
reticulum ATPase calcium pump (SERCA), totally inhib-
ited the [Ca2]i increase in differentiated and undifferen-
tiated cells. Caffeine (1 to 10mM), a ryanodine receptor
activator, had no effects on each type of cell. Finally,
contraction was never been observed with these collected
cells, indicating that MSC had not archived to a functional
smooth muscle cells phenotype.
Graft endothelialization. Immunohistologic analysis
(Fig 6) showed large positive areas for CD31 and vWF on
seeded grafts, whereas only small positive areas for CD31
and vWF were observed on nonseeded grafts (data not
shown). Moreover, cells positive for CD31 and vWF ex-
isted on the unicellular layer, as observed in the physiologic
wall. No coexpression of vWF with either GFP or anti-
smooth muscle antibody was observed in the media
layer, indicating that MSC did not give rise to these
endothelial cells. Electron microscopy showed that these
plantation: smooth muscle protein (-actin) expression.
owed smooth muscle actin expression. B, After in vivo
ctin appearance was modified in the frontal view on the
) organized in a multicellular layer mimicking media in
uorescent proteins indicating that these cells were thevo im
sis sh
scle a
ere (E
een flcells have a different morphology compared with the initial
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remained to be confirmed.
In nonseeded grafts, scanning electron microscopy
showed incomplete endothelialization, even after 2 weeks.
Collagen fibers were organized longitudinally (Fig 6), and
when endothelialization was observed, it progressed from
the periphery of the graft. In contrast, endothelialization
on seeded grafts was observed in as early as 1 week, and full
coverage of the seeded graft was observed after 2 weeks (Fig
7). The endothelial covering area was significantly in-
creased in the seeded group compared with the nonseeded
group, at 36%	 7% vs 4%	 2% (P .05) after 1 week and
80% 	 6% vs 26% 	 5% (P  .05) after 2 weeks.
DISCUSSION
These data support, for the first time to our knowledge,
that undifferentiated MSCs seeded on a graft are able to
grow in vivo and to restore a thick multicellular layer
mimicking mature vascular media. Although full SMC dif-
ferentiation was not achieved, the MSCs exerted a potent
and positive effect on vascular graft endothelialization and
yielded a monolayer of endothelial cell restoration. This
result underlies the potent, promising use of MSC-seeded
Fig 4. Messenger RNA expression of smooth muscle
chain reaction. Expression of smooth muscle proteins en
present before in vivo implantation. SM-22 and smo
protein nonexpressed in undifferentiated mesenchymal s
Glyceraldehyde-3-phosphate dehydrogenase; a-SMA, -
chain. *Significantly different P  0.05.prostheses in vascular surgery.In the present study, we first observed that undifferen-
tiated MSCs expressed smooth muscle–specific proteins
after 2 weeks in vivo. Because we could not rule out the
recruitment of local SMCs from the adjacent arterial wall,
seeded MSCs were GFP-labeled. We observed that GFP-
positive signals were coexpressed with smooth muscle–
specific protein markers, proving that the SMCs detected
and differentiated on grafts after implantation were the
initially seeded MSCs. In our study, MSCs were only in
contact with the recruited endothelial cells and no endo-
thelial differentiation was observed. Wang et al21 showed in
an in vitro model that cell-to-cell contact with mature
corresponding cells was necessary to induce smooth muscle
or cardiomyocyte differentiation, implicating the role of
integrins in extracellular matrix interaction and cell adhe-
sion mechanisms.22
Our results indicated that other factors such as pressure
and stretch may contribute to MSC differentiation in vivo
as observed in vitro.23,24 In this regard, other authors have
emphasized the influence of pressure and stretch that could
be mediated by the small Rho proteins family on vascular
differentiation.23 Hegner et al25 focused on the involve-
ment of mammalian target of rapamycin (mTOR) in the
proteins measured by reverse transcription–polymerase
d genes (a-SMA, Desmin, SM-22, MMHC-11) was still
uscle myosin heavy chain (MMHC)-11 encoding for
ells enhanced expression after in vivo staying. GAPDH,
th muscle actin; SMMHC, smooth muscle myosin heavycells
code
oth m
tem c
smooregulation of the smooth muscle phenotype of MSCs.
Ca2
ved o
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been listed.26,27 However, the precise mechanisms of in
vivo vascular MSC differentiation remain poorly under-
stood. Moreover, our data support the conclusion that
Fig 5. Functional properties of undifferentiated and in v
with mature aortic and carotid smooth muscle cells (S
iberiotoxin (IBTX) and (right panel) 4-aminopyridine
expressed in percentage of inhibition of the potassium ou
(3), andMSC (4). *Significantly different P .05.B, Ty
and (right image) after perfusion of 80mmol potassium
panel, Typical trace showing adenosine triphosphate (AT
ATP-induced Ca2 response in undifferentiated MSCs a
columns) and in absence (white columns) of extracellular
Fig 6. Confocal microscopy analysis of a graft seeded w
expression of endothelial markers. A, Before in vivo im
B, After in vivo implantation, the frontal view showed
adjacent aortic vascular wall (arrow, anastomosis). C an
CD31 and (D) von Willebrand factor, which were obserMSCs did not reach functional contractile phenotype be-cause electrophysiologic proprieties, calcium signaling, and
contraction remained quite different than mature SMCs.
Second, we observed a very interesting impact of
seeded MSCs on endothelial restoration. The impact of
ifferentiated mesenchymal stem cells (MSCs) compared
. A, Comparisons of (left panel) inhibitory effects of
P) panel at 60 mV of holding potential. Results are
current. Smoothmuscle from carotid (1) aorta (2)MSC
xample of differentiated cells in vivo (left image) before
tion. In 30 cells, no contraction was observed. C, left
duced Ca2 response in MSCs collected from the graft.
SCs isolated from grafts (in vivo), in the presence (black
. Error bars represent the standard deviation.
esenchymal stem cells after in vivo implantation shows
tation, no endothelial marker expression was attested.
31-positive area on the prosthesis that looked like the
Sagittal view showed endothelium-specific antigen (C)
nly in the first layer in contact with the artery lumen.ivo-d
MCs)
(4-A
tward
pical e
solu
P)-in
nd Mith m
plan
a CD
d D,MSC seeding on thrombogenesis observed in our study
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a scaffold containing MSCs for embedding in the carotid
and showed potential for preventing thrombosis and re-
modeling.17 In vivo endothelial differentiation of MSCs
has been evoked after myocardial transplantation or venous
implantation because these cells coexpress endothelial pro-
tein expression.28
In the present study, we obtained several lines of evi-
dence to rule out such endothelial differentiation of MSCs.
Only the superficial layers of MSC-seeded grafts were pos-
itive for CD31 or vWF, whereas the media layer was sys-
tematically negative for these markers. What is the origin of
these endothelial cells? Although endothelial cells could
arise from endothelium adjacent to the prosthesis, circulat-
ing endothelial progenitors could also contribute to pros-
thesis endothelialization. Indeed, it is known that MSCs
induce angiogenesis in myocardium after transplantation
and that their paracrine properties, including production
of several factors, such as vascular endothelial growth
factor, fibroblast growth factor-
 and stromal cell-
derived factor-1, are yet well-identified.29,30 Previous stud-
ies have shown that MSCs can promote in vitro endothelial
cell migration. However, the interactions between MSCs
and endothelial progenitors are unknown, and the precise
nature of endothelial cells covering the MSCs seeded on
grafts remains to be investigated. Finally, the use of undif-
ferentiated MSCs for endothelial restoration seems to be a
very promising tool because graft recovery of 90% of the
surface was obtained after 1 week of culture that allows
performing surgical procedures with but a short delay of
Fig 7. A, Evaluation of wall morphology by transmissio
(MSCs) formed a multilayer coat. B, Cells in contact wi
seeded cells. C, The MSCs kept their initial aspect.time.CONCLUSION
In vivo conditions induced incomplete smooth muscle
differentiation of MSCs and no endothelial differentiation.
Despite this, the monolayer of undifferentiated MSCs gave
raise to a multilayer one with an endothelium-like lumen
border. Themonitoring of endothelium restoration using a
MSC-seeded prosthesis could be a promising therapeutic
tool for vascular surgery in humans.
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